-+ 0.00%
-+ 0.00%
-+ 0.00%

Annovis Bio Data From Phase 3 Trila In Early Parkinson's Demonstrates Buntanetap Halted Cognitive Decline Across Overall Patient Count

Benzinga·11/17/2025 13:01:59
Listen to the news

Annovis Bio, Inc. (NYSE: ANVS) ("Annovis" or the "Company"), a late-stage clinical drug platform company pioneering transformative therapies for neurodegenerative diseases such as Alzheimer's disease (AD) and Parkinson's disease (PD), today announced new data demonstrating the impact of amyloid co-pathology on cognitive outcomes in Parkinson's patients and the therapeutic efficacy of buntanetap in this population.

In the Company's Phase 3 study in early PD (NCT05357989), buntanetap halted cognitive decline across the overall patient population, with the greatest improvement observed in those with mild dementia. Further analysis revealed that approximately 25% of them exhibited amyloid co-pathology and experienced more pronounced cognitive decline over the course of the study, which was counteracted and reversed by buntanetap.